Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Cardio-renal syndrome is a significant complication in acute heart failure (HF).
• The inodilator drug levosimendan's effect on renal function is debated.
• Understanding levosimendan's impact on renal hemodynamics and function is crucial for managing acute decompensated HF.

Purpose of the Study:

• To evaluate the effects of levosimendan on renal and systemic hemodynamic parameters in acute decompensated HF patients.
• To assess levosimendan's impact on renal function markers.
• To elucidate the mechanisms underlying levosimendan's renal effects.

Main Methods:

• A randomized trial involving 21 patients with acute decompensated HF and moderate renal impairment.
• Levosimendan or placebo administered alongside standard therapy.
• Systemic hemodynamics, renal blood flow (Doppler), glomerular filtration rate (GFR), cystatin C, BUN, urinary output, and sodium excretion were measured.

Main Results:

• Levosimendan significantly improved GFR, renal blood flow, and renal artery diameter compared to placebo.
• Patients receiving levosimendan showed improved BUN, creatinine, and cystatin C levels.
• Levosimendan administration led to a significant increase in urine output and favorable changes in cardiac index and pulmonary capillary wedge pressure.

Conclusions:

• Levosimendan demonstrates an immediate renoprotective effect in acute decompensated HF.
• The renoprotective effect is attributed to increased renal blood flow via selective renal arterial and venous vasodilation.
• Levosimendan offers a beneficial therapeutic option for managing cardio-renal syndrome in acute HF.